GB202106014D0 - Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients - Google Patents
Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patientsInfo
- Publication number
- GB202106014D0 GB202106014D0 GBGB2106014.0A GB202106014A GB202106014D0 GB 202106014 D0 GB202106014 D0 GB 202106014D0 GB 202106014 A GB202106014 A GB 202106014A GB 202106014 D0 GB202106014 D0 GB 202106014D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- cov
- sars
- beta
- infected patients
- improve outcome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2106014.0A GB202106014D0 (en) | 2021-04-27 | 2021-04-27 | Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients |
PCT/GB2021/051853 WO2022018422A1 (en) | 2020-07-20 | 2021-07-19 | Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients |
CN202180061898.1A CN116472054A (en) | 2020-07-20 | 2021-07-19 | Inhaled interferon-beta for improving prognosis of SARS-CoV-2 infected patient |
KR1020237005777A KR20230041097A (en) | 2020-07-20 | 2021-07-19 | Inhaled interferon-beta to improve outcomes in patients with SARS-CoV-2 infection |
JP2023504184A JP2023535710A (en) | 2020-07-20 | 2021-07-19 | Inhaled interferon-beta to improve outcomes in patients infected with SARS-CoV-2 |
EP21749262.8A EP4181944A1 (en) | 2020-07-20 | 2021-07-19 | Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients |
US18/016,964 US20230338475A1 (en) | 2020-07-20 | 2021-07-19 | USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2106014.0A GB202106014D0 (en) | 2021-04-27 | 2021-04-27 | Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202106014D0 true GB202106014D0 (en) | 2021-06-09 |
Family
ID=76193461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2106014.0A Ceased GB202106014D0 (en) | 2020-07-20 | 2021-04-27 | Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116472054A (en) |
GB (1) | GB202106014D0 (en) |
-
2021
- 2021-04-27 GB GBGB2106014.0A patent/GB202106014D0/en not_active Ceased
- 2021-07-19 CN CN202180061898.1A patent/CN116472054A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN116472054A (en) | 2023-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1208910A1 (en) | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective gpc3 gpc3 | |
GEP20166455B (en) | Methods of administering pirfenidone therapy | |
IN2012DN06616A (en) | ||
MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
NZ599246A (en) | Pirfenidone therapy and inducers of cytochrome p450 | |
MX2017012982A (en) | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes. | |
NZ599511A (en) | Recombinant human cc10 protein for treatment of influenza | |
MX2020011107A (en) | Glycosidase regimen for treatment of infectious disease. | |
EP4112050A4 (en) | Use of nucleoside compound in treatment of coronavirus infectious diseases | |
BR112014007580A2 (en) | medical intervention device and method of manufacture | |
GB202302767D0 (en) | Improvements in or relating to patient care | |
GB202106014D0 (en) | Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients | |
GB202011284D0 (en) | Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients | |
GB202011216D0 (en) | Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients | |
MX2019002657A (en) | Combinations with a backbone-cyclized peptide. | |
MX2019002894A (en) | Combinations with a backbone-cyclized peptide. | |
IL308992A (en) | Treatment of cancer in patients with soluble fr-alpha | |
RU2013129824A (en) | NEW TREATMENT OF HEPATITIS C VIRUS INFECTION | |
MX2022007908A (en) | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv. | |
PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
GB202100322D0 (en) | Artificial up-regulation of EGR1 protein in COVID19 infected lung tissues as a therapeutic treatment | |
GB202303291D0 (en) | Medicament and medicament combination for use in the treatment of infectious disease | |
ZA202201362B (en) | Use of dihydroartemisinin and gypenoside-l in manufacture of medicament for resisting tumor | |
陈可冀 | New findings validate an ancient technique: how massage affects the biochemistry of inflammation | |
UA47947U (en) | Method for treating chronic viral hepatitis b and c in children |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |